Skip to main content
03/10/2023

The UNDINE project on the determinants of COVID-19 manifestations holds its annual meeting

Projecte UNDINE

Annual meeting of UNDINE project.

Projecte UNDINE

Annual meeting of UNDINE project.

03/10/2023

The meeting, in which Dr. Pere Soler participated, showed the results of the first year with the description of new genetic defects associated with severe forms of COVID-19 and novelties in the detection of autoantibodies against interferons.

On September 19, the annual meeting of the international project UNDINE (“The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infection: Towards personalized medicine") was held to learn about the factors related to the different manifestations of COVID-19. This project is funded by a European H2020 grant. This meeting, held in Vejle (Denmark), was attended by Dr. Pere Soler Palacín, head of the Pediatric Infectious Pathology and Immunodeficiency Unit of the Vall d'Hebron University Hospital and of the Infection and Immunity in the Pediatric Patient group of the Vall d'Hebron Research Institute (VHIR) and coordinator of one of the work packages (WP1).

The aim of the UNDINE project is to decipher the human genetic and immunological basis of the different manifestations of disease by SARS-CoV-2 and to gain a broad understanding of the pathogenesis of SARS-CoV-2 in order to identify individuals at increased risk of critical COVID-19, post-infectious immunological complications and vaccine failure. The project works to provide a basis for the development of diagnostic tests and propose new preventive and therapeutic approaches. "The involvement of professionals from different fields of research in the participating countries allows us to advance more quickly and share the findings in order to allow a direct benefit in healthcare practice", says Dr. Pere Soler Palacín.

At this meeting, the results of the first year of the project were presented, with the description of new genetic defects associated with severe forms of COVID-19 and also with multisystemic inflammatory syndrome in children and adults, as well as novelties in the detection of autoantibodies against interferons as the cause of severe COVID-19 at different ages. In addition, host-specific factors that have allowed so-called "resistant" individuals to avoid SARS-CoV-2 infection despite repeated exposure to the virus and genetic variants associated with prolonged COVID-19 continue to be investigated.

The Infection and Immunity in the Pediatric Patient group works, as part of the ICS node together with the Germans Trias i Pujol Research Institute (IGTP) and the Bellvitge Biomedical Research Institute (IDIBELL), in several work packages of this international project but mainly in WP1, led by Dr. Pere Soler Palacín and Dr. Isabelle Meyts from the University of Leuven in Belgium. This work package is dedicated to the establishment and follow-up of clinical cohorts used in all the experiments of the project, covering multiple clinical phenotypes related to SARS-CoV-2 infection.

Related news

So far, 240 volunteers have been recruited within all the centres set to join adolescents’ clinical trial (named HH3) to test the efficacy, tolerability, and safety of the BIMERVAX® COVID-19 vaccine in adolescents aged 12 to 17.

The results show that, in some patients with mutations in the X chromosome, the healthy gene is inactivated and the mutated gene manifests itself, which favors the onset of the disease.

The study, which is part of the European RECOMB project, is currently recruiting volunteers.

Related professionals

Pere Soler Palacín

Pere Soler Palacín

Head of group
Infection and immunity in pediatric patients
Read more
Sonia Galindo Maycas

Sonia Galindo Maycas

Read more
Rello Saltor, Victoria

Rello Saltor, Victoria

Research technician
Infection and immunity in pediatric patients
Read more
Maria Pinyol Sarrias

Maria Pinyol Sarrias

Predoctoral researcher
Infection and immunity in pediatric patients
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.